Abbott Laboratories (ABT) Q3 2026 Earnings Call: Q&A Summary

Q: Robert Marcus from JPMorgan asked for the strategic rationale behind the Nutrition spin-off and why the company chose a spin over a sale.

A: Robert Ford explained that the nutrition market is evolving toward healthy nutrition, requiring independent focus and investment to maximize potential. He stated that a spin-off is preferred over a sale to avoid tax implications and maintain control over the asset.

Q: Larry Biegelsen from Wells Fargo asked if the net liability for litigation would remain with Abbott.

A: Robert Ford stated that resolving litigation is not a prerequisite for the separation and that both Abbott and the new Nutrition company will be well-capitalized to manage their respective legal positions.

Q: Joanne Wuensch from Citi asked if the pending spin impacts other strategic plans such as future M&A.

A: Robert Ford confirmed the spin has no negative impact on M&A, noting that Abbott retains a strong balance sheet and will continue to pursue tuck-in acquisitions.

Q: Larry Biegelsen from Wells Fargo asked about the drivers of the revenue guidance reduction and the implications for 2027.

A: Robert Ford attributed the reduction to Electrophysiology, due to LAA market headwinds, and Diabetes, due to pricing pressure and lack of reimbursement expansion. He noted that 2027 guidance will be conservative and similar to 2026.

Q: Vijay Kumar from Evercore ISI asked if investors should still aim for double-digit EPS growth for fiscal 2027.

A: Robert Ford stated that specific guidance for 2027 will be provided in January.

Q: Patrick Andrew Wood from UBS asked how the current pipeline compares to the past and which areas are a personal focus.

A: Robert Ford noted that R&D spend is over $3 billion and highlighted focus areas including Aveir CSP, mitral replacement, Libre platform expansion, EPD biosimilars, and cancer diagnostics.

Q: Travis Steed from BofA Securities asked about the upcoming TCT conference readouts for Amulet 360 and coronary IVL.

A: Robert Ford emphasized that Amulet 360 and IVL are key growth drivers, adding that the IVL acquisition from CSI will help accelerate growth in the Vascular business.

Q: Matt Taylor from Jefferies asked about trends in cancer diagnostics, specifically Cologuard and the new blood test.

A: Robert Ford explained that a July cyber event impacted growth by 1 point, but Cologuard grew mid-teens. He noted the blood-based test launched September 30.

Q: Vijay Kumar from Evercore ISI asked about Cologuard 2.0 reimbursement and the ASP for the new blood test.

A: Robert Ford stated it is unlikely Cologuard Plus reimbursement will decrease and declined to disclose the blood test ASP.

Q: Joanne Wuensch from Citi asked about potential CMS reimbursement for non-insulin type 2 CGM use.

A: Robert Ford said he cannot forecast the timing of CMS reimbursement for non-insulin type 2 patients, though he acknowledged the clinical support for the technology.